# Becton Dickinson: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Becton, Dickinson and Company · NYSE: BDX · Sector: Health Care

Updated for Q4 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/becton-dickinson. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Becton Dickinson: how the business works", with the page URL.

## The 30-second summary

Becton Dickinson makes syringes, IV catheters, blood-collection tubes, infusion pumps and dispensing cabinets, with FY2026 revenue of $19,457 million (unaudited). Of every $100 that came in, making the products took $52.3 and $7.2 was left as net income from continuing operations. On Feb 9, 2026 BD combined its diagnostics business with Waters and received $4 billion. It ended FY2026 with $16,345 million of debt.

## 5 points

- **What it sells:** BD sells hospital disposables and equipment, with FY2026 revenue of $19,457 million: 34.5% from Medical Essentials, 28.6% Interventional, 24.4% Connected Care and 12.5% BioPharma Systems. [S16]
- **Who pays it:** BD names no single large customer and gives no split by customer type; by location, US customers paid 62% of FY2026 revenue and international customers 38%. [S4, S16]
- **What it keeps from $100:** Of every $100 that came in during FY2026, BD kept $7.2 as net income from continuing operations after $4.1 of integration, restructuring and deal costs; operating income was $11.6 per $100 of revenue. [S16]
- **Where the operating profit comes from:** BD has not yet given FY2026 operating income by segment; by revenue, Medical Essentials was the largest at $6,703 million and Interventional grew fastest, up 6.8%. [S16]
- **The one thing to watch:** BD guided on Nov 5, 2026 to FY2027 adjusted diluted EPS of $13.10 to $13.30, against $12.70 in FY2026, after $806 million of integration, restructuring and deal costs in FY2026. [S16]

## What does Becton Dickinson sell?

BD makes everyday disposable medical items for hospitals, such as syringes, IV catheters and blood-collection tubes. It also sells hospital equipment like infusion pumps and medicine-dispensing cabinets, and syringes that drugmakers pre-fill with their drugs.

- **Medical Essentials:** Syringes, needles, IV catheters and blood-collection tubes for hospitals and labs: $6,703 million, the largest segment in FY2026. [S16, S4]
- **Connected Care:** Alaris infusion pumps, Pyxis medicine-dispensing cabinets, pharmacy robots and patient monitors bought from Edwards Lifesciences in 2024: $4,745 million in FY2026. [S16, S4]
- **BioPharma Systems:** Prefillable syringes sold to drug companies, which fill them with drugs such as GLP-1 weight-loss and diabetes treatments: $2,437 million in FY2026. [S16, S1]
- **Interventional:** Hernia mesh, ChloraPrep skin antiseptic, balloons and stents for blood vessels, and urology catheters: $5,573 million in FY2026. [S16, S4]

## Who pays Becton Dickinson?

- **Hospitals and health systems:** Buy disposables, mostly through distributors in the US, and buy or lease pumps and dispensing equipment, mostly sold direct. [S4]
- **Drug companies (12.5% of revenue):** Buy prefillable syringes for their injectable drugs; BioPharma Systems was 12.5% of FY2026 revenue. [S16]
- **Distributors:** Acute care, non-acute care, laboratory and drug wholesalers resell BD disposables in the US; abroad BD sells direct or through distributors. [S4]
- **Labs and clinics:** Buy blood-collection tubes and needles; Specimen Management sold $1,992 million in FY2026. [S16]
- **Customer concentration:** No customer accounted for 10% or more of revenue in FY2023, FY2024 or FY2025, the FY2025 10-K says. BD does not give a split by customer type. [S4]

## Where the money went (FY2026)

1. Hospitals, distributors, labs and drugmakers paid BD $19,457 million in FY2026.
2. Making the products took $10,243 million, and selling them $4,965 million.
3. Research, the cost of separating from the Waters business and other items took $1,993 million more.
4. After $564 million of interest and $388 million of tax, $1,417 million was left from continuing operations.

Sources: S16.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Sep 30 (October to September). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 (restated) | 19,131 | 4,480 | 23.4% | 2,092 | 10.9% | 6.85 | 4,647 | 1,194 | 3,453 | S12, S14 |
| FY2022 | 18,870 | 4,511 | 23.9% | 1,779 | 9.4% | 5.88 | 2,471 | 973 | 1,498 | S13 |
| FY2023 | 19,372 | 4,399 | 22.7% | 1,484 | 7.7% | 4.94 | 2,990 | 874 | 2,116 | S12 |
| FY2024 | 20,178 | 4,683 | 23.2% | 1,705 | 8.4% | 5.86 | 3,844 | 725 | 3,119 | S8 |
| FY2025 | 21,840 | 5,041 | 23.1% | 1,678 | 7.7% | 5.82 | 3,430 | 760 | 2,670 | S4 |
| FY2026 (After Waters spin-off; unaudited) | 19,457 | 4,495 | 23.1% | 1,145 | 5.9% | 4.09 | 3,605 | 672 | 2,933 | S16 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Debt of $16,345 million at Sep 30, 2026 was about 4.5 years of FY2026 operating cash flow, down from $19,179 million a year earlier. [S16, S1]

| Item | Value |
| --- | --- |
| Total debt | 16,345 |
| Cash and investments | 733 |
| Net debt (debt minus cash) | 15,612 |
| Net worth (shareholders' money) | 24,682 |
| Debt to equity (times) | 0.66 |
| Interest cover (times) | 4.2 |

- Net debt (debt minus $725 million cash and $8 million short-term investments; restricted cash left out), debt-to-equity, interest cover (operating income of $2,257 million divided by interest expense net of interest income, $537 million) and years of cash flow are Cityfort calculations from the Q4 FY2026 earnings release, which is unaudited.
- About $2 billion of the $4 billion cash BD received in the Waters deal went to repaying debt (Q3 FY2026 10-Q).
- BD has a $2,750 million revolving credit line to Sep 2030; its loan terms cap leverage (debt measured against earnings) at 4.25 times (Q3 FY2026 10-Q).

## Who owns Becton Dickinson? (as of Dec 8, 2025)

One vote per share and no controlling holder. Directors and executive officers as a group held 1,134,105 shares, under 1% (0.4% is a Cityfort calculation from the 2026 proxy statement). Holder dates differ, so the rows are not added up. [S15, S24, S25, S1]

- Officers and directors (as a group), shares: 0.4%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (272,386,800 shares on the Q3 FY2026 10-Q cover, down from 284,908,096 at the proxy record date of Dec 8, 2025 after the 2026 buybacks. One class, listed on the NYSE.) | 272.4 | 1 | — | — | Yes | S1, S15 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 11.3% | — | Jun 30, 2025 | 2026 proxy figure from a Schedule 13G/A filed Jul 7, 2025: 32,308,728 shares. | S15 |
| BlackRock, Inc. | 7.9% | — | Dec 31, 2023 | 2026 proxy figure from a Schedule 13G/A filed Jan 26, 2024: 22,774,866 shares. No newer filing is held for this page. | S15 |
| T. Rowe Price Investment Management | 5.6% | — | Jun 30, 2025 | 2026 proxy figure from a Schedule 13G filed Aug 14, 2025: 16,178,519 shares. | S15 |
| State Street Corporation | 5.4% | — | Jun 30, 2026 | Schedule 13G filed Aug 7, 2026. | S24 |
| First Eagle Investment Management | 5.1% | — | Jun 30, 2026 | Schedule 13G filed Aug 6, 2026. | S25 |

## What could go wrong

### Ethylene oxide lawsuits in Georgia

About 435 suits from about 445 people near its Covington sterilization site allege cancers and other injuries from ethylene oxide (Jun 30, 2026). In the first trial a jury awarded one plaintiff $20 million in compensatory damages in May 2025; no judgment has been entered, and BD's appeal of a trial-court ruling in the case was argued on May 14, 2026, the Q3 FY2026 10-Q says. BD says it has meritorious defenses. [S1]

What to watch: The Georgia Court of Appeals decision (argued May 14, 2026) and later trials.

### FDA quality actions

Its infusion pumps operate under an FDA consent decree, and warning letters were issued to its San Diego dispensing site (Nov 2024) and El Paso plant (Apr 30, 2026). The 10-Q says the El Paso work added costs in Interventional. [S1]

What to watch: Any new FDA letter, recall or change to the consent decree.

### Debt level

Debt was $16,345 million at Sep 30, 2026 against $3,605 million of operating cash flow in FY2026. Its credit line caps leverage at 4.25 times. [S16, S1, S4]

What to watch: Debt at each quarter end and any change to its BBB / Baa2 ratings.

### Tariffs

The Q3 FY2026 10-Q says tariffs hurt results and margins. The tariff relief in BD's Nov 5, 2026 US government deal depends on the final scope and on BD meeting agreed milestones. [S1, S16]

What to watch: Gross profit per $100 of revenue each quarter and updates on the US investment plan.

### Price pressure from hospitals and governments

The 10-K warns that merging health systems gain buying power and governments try to limit healthcare costs. Italy requires device makers to repay part of sales when regional budgets are exceeded; amounts for 2019 onward are unresolved. [S4, S1]

What to watch: Revenue growth excluding currency, by segment.

### Separation and restructuring costs

Integration, restructuring and deal costs were $806 million in FY2026, double the $403 million in FY2025, and continuing operations lost $37 million in Q2 FY2026. [S16, S18]

What to watch: Whether these costs fall in FY2027 results.

## What to watch

Next: Q1 FY2027 results, Date not announced yet.

- **Investor Day on Dec 10, 2026:** BD said in its Q4 FY2026 release that it will hold an Investor Day at the New York Stock Exchange on Dec 10, 2026.
- **FY2027 results against guidance:** BD said on Nov 5, 2026 that it expects low single-digit revenue growth and adjusted diluted EPS of $13.10 to $13.30 in FY2027; it reported $12.70 for FY2026.
- **The audited FY2026 10-K:** FY2026 figures on this page come from the unaudited Nov 5, 2026 release; the 10-K had not been filed by Nov 20, 2026.
- **Ethylene oxide appeal:** BD's appeal of a trial-court ruling in the first ethylene oxide case (argued May 14, 2026; no judgment entered, per the Q3 FY2026 10-Q); about 435 suits were pending at Jun 30, 2026.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/0000010795-26-000035-index.htm (published Aug 6, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079526000026/0000010795-26-000026-index.htm (published May 7, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079526000005/0000010795-26-000005-index.htm (published Feb 9, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.htm (published Nov 25, 2025)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079525000072/0000010795-25-000072-index.htm (published Aug 7, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079525000039/0000010795-25-000039-index.htm (published May 1, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079525000022/0000010795-25-000022-index.htm (published Feb 6, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079524000084/0000010795-24-000084-index.htm (published Nov 27, 2024)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079524000067/0000010795-24-000067-index.htm (published Aug 1, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079524000039/0000010795-24-000039-index.htm (published May 2, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079524000019/0000010795-24-000019-index.htm (published Feb 1, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079523000098/0000010795-23-000098-index.htm (published Nov 21, 2023)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828022030686/0001628280-22-030686-index.htm (published Nov 22, 2022)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000001079521000091/0000010795-21-000091-index.htm (published Nov 24, 2021)
- S15: Proxy statement (DEF 14A) for the 2026 annual meeting. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828225057846/bdx-20251217.htm (published Dec 18, 2025)
- S16: Q4 and full-year FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828226070511/ex9919302026.htm (published Nov 5, 2026)
- S17: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828226053790/ex9916302026.htm (published Aug 6, 2026)
- S18: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828226031638/ex9913312026.htm (published May 7, 2026)
- S19: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828226006182/ex99112312025.htm (published Feb 9, 2026)
- S20: 8-K filed Apr 2, 2026: recast quarterly results for continuing operations after the Waters spin-off (Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828226023185/ex991042026.htm (published Apr 2, 2026)
- S21: 8-K filed Feb 9, 2026: completion of the Biosciences and Diagnostic Solutions combination with Waters (Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000119312526042827/d104936dex991.htm (published Feb 9, 2026)
- S22: 8-K filed Jul 22, 2026: officer retirement (Item 5.02). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000162828026049103/bdx-20260719.htm (published Jul 22, 2026)
- S23: 8-K filed Jul 14, 2025: agreement to combine Biosciences and Diagnostic Solutions with Waters. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000119312525158797/d822749d8k.htm (published Jul 14, 2025)
- S24: Schedule 13G, State Street Corporation (5.4% as of Jun 30, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000009375126000419/primary_doc.xml (published Aug 7, 2026)
- S25: Schedule 13G, First Eagle Investment Management (5.1% as of Jun 30, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/10795/000132544726000023/primary_doc.xml (published Aug 6, 2026)
